Tumor necrosis factor alpha mediates homogeneous distribution of liposomes in murine melanoma that contributes to a better tumor response
- PMID: 17909055
- DOI: 10.1158/0008-5472.CAN-07-1599
Tumor necrosis factor alpha mediates homogeneous distribution of liposomes in murine melanoma that contributes to a better tumor response
Abstract
Successful treatment of solid tumors with chemotherapeutics requires that adequate levels reach the tumor cells. Tumor vascular normalization has been proposed to enhance drug delivery and improve tumor response to chemotherapy. Differently, augmenting leakage of the tumor-associated vasculature, and as such enhance vascular abnormality, may improve tumor response as well. In the present study, we show that addition of low-dose tumor necrosis factor alpha (TNF) to systemic injections with pegylated long circulating liposomes augmented the tumor accumulation of these liposomes 5- to 6-fold, which strongly correlated with enhanced tumor response. Using intravital microscopy, we could study the liposomal distribution inside the tumor in more detail. Especially 100 nm liposomes effectively extravasate in the surrounding tumor tissue in the presence of TNF and this occurred without any effect on tumor vascular density, branching, and diameter. Next to that, we observed in living animals that tumor cells take up the liposomes intact, followed by intracellular degradation. To our knowledge, this is an unprecedented observation. Taken together, TNF renders more tumor vessels permeable, leading to a more homogeneous distribution of the liposomes throughout the tumor, which is crucial for an optimal tumor response. We conclude that delivery of nanoparticulate drug formulations to solid tumor benefits from augmenting the vascular leakage through vascular manipulation with vasoactive drugs like TNF.
Similar articles
-
Crucial role for interferon gamma in the synergism between tumor vasculature-targeted tumor necrosis factor alpha (NGR-TNF) and doxorubicin.Cancer Res. 2004 Oct 1;64(19):7150-5. doi: 10.1158/0008-5472.CAN-04-1445. Cancer Res. 2004. PMID: 15466213
-
Experimental anticancer therapy with vascular-disruptive peptide and liposome-entrapped chemotherapeutic agent.Arch Immunol Ther Exp (Warsz). 2010 Jun;58(3):235-45. doi: 10.1007/s00005-010-0077-y. Epub 2010 Apr 11. Arch Immunol Ther Exp (Warsz). 2010. PMID: 20383751
-
Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration.J Clin Invest. 2002 Aug;110(4):475-82. doi: 10.1172/JCI15223. J Clin Invest. 2002. PMID: 12189241 Free PMC article.
-
Tumor vascular targeting with tumor necrosis factor alpha and chemotherapeutic drugs.Ann N Y Acad Sci. 2004 Dec;1028:104-12. doi: 10.1196/annals.1322.011. Ann N Y Acad Sci. 2004. PMID: 15650236 Review.
-
Tumor necrosis factor-mediated interactions between inflammatory response and tumor vascular bed.Immunol Rev. 2008 Apr;222:299-315. doi: 10.1111/j.1600-065X.2008.00619.x. Immunol Rev. 2008. PMID: 18364010 Review.
Cited by
-
Hyperthermia and Temperature-Sensitive Nanomaterials for Spatiotemporal Drug Delivery to Solid Tumors.Pharmaceutics. 2020 Oct 22;12(11):1007. doi: 10.3390/pharmaceutics12111007. Pharmaceutics. 2020. PMID: 33105816 Free PMC article. Review.
-
PEGylated Liposomes Accumulate in the Areas Relevant to Skin Toxicities via Passive Extravasation across "Leaky" Endothelium.ACS Nano. 2022 Apr 26;16(4):6349-6358. doi: 10.1021/acsnano.2c00423. Epub 2022 Mar 28. ACS Nano. 2022. PMID: 35343675 Free PMC article.
-
Liposomes targeted to MHC-restricted antigen improve drug delivery and antimelanoma response.Int J Nanomedicine. 2019 Mar 26;14:2069-2089. doi: 10.2147/IJN.S190736. eCollection 2019. Int J Nanomedicine. 2019. PMID: 30988609 Free PMC article.
-
Challenges associated with Penetration of Nanoparticles across Cell and Tissue Barriers: A Review of Current Status and Future Prospects.Nano Today. 2014 Apr 1;9(2):223-243. doi: 10.1016/j.nantod.2014.04.008. Nano Today. 2014. PMID: 25132862 Free PMC article.
-
Thermosensitive liposomes for localized delivery and triggered release of chemotherapy.J Control Release. 2013 Jul 10;169(1-2):112-25. doi: 10.1016/j.jconrel.2013.03.036. Epub 2013 Apr 11. J Control Release. 2013. PMID: 23583706 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources